Olufunmilayo I. Olopade

Jan 15, 2025 | thelancet.com | Olufunmilayo I. Olopade

Breast cancer is the most common neoplastic disease and leading cause of cancer mortality in women.1 Global estimates have recorded regional variations in the burden of breast cancer, but none have been disaggregated by menopausal status.1 In The Lancet Global Health, Emily Heer and colleagues2 contribute to the body of evidence on global disparities in outcomes, with particular reference to breast cancer incidence and survival by menopausal status and by a country's human development index...

Jul 31, 2024 | ascopost.com | Olufunmilayo I. Olopade

I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social justice and his determination to end apartheid in South Africa. She was a true freedom fighter in the Mandela tradition.

Nov 29, 2023 | nature.com | Beth Karlan |Olufunmilayo I. Olopade |Christian F. Singer |Susan Neuhausen |Charis Eng |Steven A. Narod

AbstractRisk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited data on the impact on breast cancer mortality. Participants were identified from a registry of women with BRCA1/2 pathogenic variants. We used a pseudo-randomised trial design and matched one woman with a RRM to one woman without a RRM on year of birth, gene, and country.

Apr 14, 2023 | nature.com | Frederick Howard |James M. Dolezal |Andrew Srisuwananukorn |Rita Nanda |Charles M. Perou |Olufunmilayo I. Olopade | +2 more

AbstractGene expression-based recurrence assays are strongly recommended to guide the use of chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing is expensive, can contribute to delays in care, and may not be available in low-resource settings. Here, we describe the training and independent validation of a deep learning model that predicts recurrence assay result and risk of recurrence using both digital histology and clinical risk factors.

Mar 30, 2023 | jamanetwork.com | Sarah Shubeck |Fangyuan Zhao |Frederick Howard |Olufunmilayo I. Olopade

Key PointsQuestion  Are there racial and ethnic differences in response to neoadjuvant chemotherapy of breast cancer that may have survival implications? Findings  In this cohort study of 107 207 patients with stage I to III breast cancer, significant racial and ethnic differences in pathologic complete response rates were observed. These racial and ethnic differences were subtype-specific and were found to account for a substantial portion of the identified survival disparity.